呼吸道合胞病毒抑制剂研究新进展  

New progress in research on respiratory syncytial virus inhibitors

作　　者：徐淑静 刘新泳[1] 展鹏[1] XU Shu-jing;LIU Xin-yong;ZHAN Peng(Department of Medicinal Chemistry,Key Laboratory of Chemical Biology(Ministry of Education),School of Pharmaceutical Sciences,Shandong University,Jinan 250012,China)

机构地区：[1]山东大学药学院药物化学研究所,化学生物学教育部重点实验室,山东济南250012

出　　处：《药学学报》2020年第4期597-610,共14页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金项目(81420108027,81573347);山东省重点研发计划(2017CXGC1401,2019JZZY021011)。

摘　　要：呼吸道合胞病毒(RSV)是引起婴幼儿、老年人和免疫功能低下者呼吸道感染的主要病原体。目前,利巴韦林和人源化单克隆抗体帕利珠常用于RSV引发的下呼吸道感染,但由于它们的疗效、经济性与安全性等问题限制了其临床应用。因此需要开发新型的RSV抑制剂来满足临床预治的需求。本文精选典型研究案例,从药物化学的角度综述了不同靶点RSV抑制剂的研究进展。Respiratory syncytial virus(RSV)is the main pathogen causing respiratory infections in infants,the elderly,and immunocompromised individuals.Currently,ribavirin and the humanized monoclonal antibody palivizumab are commonly used for lower respiratory tract infections caused by RSV.However,their clinical application has been limited by their efficacy,economy and safety.Therefore,it is necessary to develop new RSV inhibitors to meet the needs of clinical prevention and treatment.This paper selects typical research cases and reviews the research progress of different target inhibitors from the perspective of medicinal chemistry.

关 键 词：呼吸道合胞病毒 抗病毒疗法 药物靶点 抑制剂 

分 类 号：R916[医药卫生—药学]